Literature DB >> 1365818

Free levonorgestrel index and its relationship with luteal activity during long-term use of Norplant implants.

V Brache1, F Alvarez-Sanchez, A Faundes, A S Tejada, L Cochon.   

Abstract

Levonorgestrel serum levels and sex hormone binding globulin (SHBG) were measured in 82 women during different years of use of Norplant implants. The ratio between levonorgestrel and SHBG was calculated as an indicator of the free biologically active fraction of levonorgestrel (free levonorgestrel index, FLI). These parameters were then correlated with the presence of luteal activity, as determined by progesterone levels above 9.6 nmol/L, in a sampling run of 10 samples taken twice a week for five consecutive weeks. Levonorgestrel serum levels remained constant around 1.0 nmol/L during the five-year period. SHBG levels were below normal for the first 18 months of use, returning to normal levels during the last three years of use. The FLI in the first two years was significantly higher than that observed in the later years. The frequency of cycles with luteal activity was 12% during the first 2 years, increasing to 44% in the latter years, when FLI levels were lower. Our results suggest that the changes in SHBG and consequently in the free biologically active fraction of levonorgestrel may largely account for the differences in degree of ovarian suppression observed between the first two years of use of Norplant implants and the latter three, even in the absence of a significant variation in total levonorgestrel concentrations.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1365818     DOI: 10.1007/bf02042590

Source DB:  PubMed          Journal:  Adv Contracept        ISSN: 0267-4874


  3 in total

1.  Cohort study to evaluate efficacy, safety and acceptability of a two-rod contraceptive implant during third, fourth and fifth year of product use in China.

Authors:  Y Che; D Taylor; D Luo; L Y Maldonado; M Wang; S Wevill; H Vahdat; X Han; V Halpern; L Dorflinger; M J Steiner
Journal:  Contracept X       Date:  2019

2.  Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.

Authors:  Andrea Ries Thurman; Jill L Schwartz; Vivian Brache; Meredith R Clark; Timothy McCormick; Neelima Chandra; Mark A Marzinke; Frank Z Stanczyk; Charlene S Dezzutti; Sharon L Hillier; Betsy C Herold; Raina Fichorova; Susana N Asin; Christiane Rollenhagen; Debra Weiner; Patrick Kiser; Gustavo F Doncel
Journal:  PLoS One       Date:  2018-06-28       Impact factor: 3.240

3.  Randomized trial to evaluate contraceptive efficacy, safety and acceptability of a two-rod contraceptive implant over 4 years in the Dominican Republic.

Authors:  M J Steiner; V Brache; D Taylor; R Callahan; V Halpern; A Jorge; S Wevill; J Sergison; L Venkatasubramanian; L Dorflinger
Journal:  Contracept X       Date:  2019
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.